Mikhail Blagosklonny is More Than Just an Oncologist

For the majority of his career, Mikhail Blagosklonny has been helping people who are dealing with cancer. He has done what he can to make their lives better and to help them with the issues that they have but he has not been able to provide them with just simple treatment methods. Instead, he has done so much more than that so that he will be able to make a big difference in the cancer treatment community. He has come a long way from when he was just trying to do basic research on his own and the new methods that he has learned about have been enough to get him through many difficult patient experiences.Most of the information that Mikhail Blagosklonny finds on cancer treatment comes from Oncotarget. This is where he gets his information from and where he is comfortable with information from. There are many specialists who are a part of the publication and who have worked hard so that they can help each other with the peer review aspect of the publication.

Mikhail Blagosklonny knows a lot about the things that are going on and about the way that the specialists are able to help each other learn about the things that they can do to treat issues.Mikhail Blagosklonny has always done the things that he can to help people and Oncotarget was his idea of making sure that specialists would be able to connect. He was confident that the publication would give people a chance to talk with each other and to open up discussions about research that they had never been able to have in the past. Mikhail Blagosklonny was confident in the fact that specialists needed a way to be able to interact with each other. He wanted to be sure that people would have a chance at the best cancer treatment possible.

Since there are so many different areas of cancer that people can specialize in, it was easy for Mikhail Blagosklonny to make Oncotarget start out with the options that he intended for it. He wanted to make sure that oncologists got the best treatment information possible and that they could use ideas from other oncologists to learn more about the right way to treat. He also wanted to give them a chance to publish their research somewhere that was guaranteed to have many people looking at it.Mikhail Blagosklonny realized that this was not the only way to do a peer review publication. He wanted to show people that they could do more and he wanted to make sure that people would be able to learn from other areas of medicine. For that reason, he began to include other specialists. He asked them to do research and to figure out what they could do to help each other learn. Since then, he has been able to make things better so that people will be able to learn more about the different things that are going on in medicine and how they can treat diseases.

Tempus is Helping to Fight Cancer Using Data-Enabled Precision Medicine

Many US Citizens every year develop some kind of cancer including children. Eric Lefkofsky, co-founder of Tempus, is leading the fight against this disease by using data enabled precision medicine. In 2014, approximately 14.5 million people in the United States were diagnosed as having cancer.

In the past, the healthcare industry was more concerned about electronic medical records (EMR) instead of treating cancer patients. Back when Eric Lefkofsky got involved in helping find a cure for cancer is when his wife was diagnosed with breast cancer. He discovered that there was a gapping hole in terms of data collection and digital technology in the following:  http://lefkofskyfoundation.com/ click here.

Until Tempus came into existence, there was still a lot of work to be done with data collection and digital technology. Tempus has created a unique platform in analyzing patient’s clinical and molecular data. The company had come up with developing the analytics software; however, there was a lack of funding.

Another difficulty was how to access crucial information in regards to how data was stored cancer patients. Most of the time, the information was found in physicians’ notes, leaving it difficult to analyze the data needed. Tempus developed a software that has natural language processing and optical character recognition capabilities. Finally, the information could be transferred from physicians’ notes into structured data.

The molecular data, which is called genomic information is collected through human genomic sequencing. Compared to $100 million in 2003, now this software has gone down to $5000 and will continue to go down in price thanks to science and technology.

Tempus is leading the fight to finding cure for treating cancer by using genomic sequencing. Human genes hold the clue to finding a cure for different kinds of diseases, like cancer. The Tempus Company is using software allowing clinical information, regarding the patient, to be treated with molecular information through genomic sequencing.

There will come a time, in the future, thanks to the Tempus Company, doctors will be able to diagnose diseases more effectively, like cancer through data-enabled precision medicine. Then doctors will have more effective treatments that will work thanks to Eric Lefkofsky, co-founder of Tempus.

How Clay Siegall Has Supported The Growth Of Cancer Research

 

The fight to defeat cancer has seen many people make effort to deliver solutions that can be used in the long term to help patients. One of the individuals who have stood out in this regard is Clay Siegall, who has invested a lot in cancer research and the development of products that are meant to offer easier and highly reliable methods of treating cancer. As a clinical scientist with over 20 years experience, Clay Siegall has helped many experts who work under him to pursue research projects that later led to the development of useful drug pipelines.

He founded Seattle Genetics in 1998 and has been working as the President and CEO of the company. His leadership has been a major boost to the development of the company and the engineering of solutions that are powerful and meant to advance the fight to find better ways of treating cancer. Through his company, Clay Siegall has launched several technologies and one of the most notable is the ADC Technology, which was rated perfectly as a solution to the many challenges that have been preventing the successful administration of treatment to cancer patients. The technology works by carefully selecting the harmful cells and destroying them while discriminating against the healthy ones.

About Clay Siegall

Clay Siegall, who has worked in the field of biotechnology for over 20 years, is the founder and CEO of renowned biotechnology company, Seattle Genetics. He is a passionate researcher and his support for cancer research led to the development of powerful solutions for the treatment of cancer. Clay Siegall has also been inviting support to make the process a success and in this bid, he was able to launch the ADC Technology and ADCETRIS, which have proved useful in the fight against cancer.

His educational background places him among clinical scientists. He first earned a bachelor’s degree in Zoology at the University of Maryland then later joined the University of Washington for a PhD degree in Genetics. He sharpened his skills along the way while working with several companies and corporations like the National Institute of Health.